2006
DOI: 10.1124/mol.105.018804
|View full text |Cite
|
Sign up to set email alerts
|

Soluble Mimics of the Cytoplasmic Face of the Human V1-Vascular Vasopressin Receptor Bind Arrestin2 and Calmodulin

Abstract: Signal transduction by G protein-coupled receptors (GPCRs) is mediated by interactions between intracellular proteins and exposed motifs on the cytoplasmic face of these receptors. Arrestins bind to GPCRs and modulate receptor function either by interfering with heterotrimeric G protein signaling or by serving as signaling adaptors themselves. Calmodulin interacts with GPCRs triggering a calcium response. We have studied the interaction of arrestin2 and calmodulin with intracellular elements of the human V1-va… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2006
2006
2014
2014

Publication Types

Select...
4
1

Relationship

1
4

Authors

Journals

citations
Cited by 5 publications
(1 citation statement)
references
References 41 publications
(31 reference statements)
0
1
0
Order By: Relevance
“…When the key phosphorylation sites of CXCR2 that are involved with its desensitization were mutated to alanine residues (4A mutant), the receptor mutant bound weakly to β‐arrestin1 (41% reduction), but exhibited normal binding to AP2 in comparison with WT‐CXCR2 (Figure B). The CXCR2 receptor with both IL/AA (mutant deficient in AP2 binding) and 4A (mutant with reduced binding to β‐arrestin) mutations, designated ‘4A/IL’ mutant, displayed reduced binding to AP2 (64% reduction) as expected and even further reduced binding of β‐arrestin1 (90% reduction), in comparison to the 4A mutant (Figure B) even though β‐arrestin is known to bind with low affinity to GPCRs through the intracellular loops of the receptor . The deficiency of binding of the AP‐2 complex to IL/AA‐CXCR2 mutant has been shown previously .…”
Section: Resultsmentioning
confidence: 81%
“…When the key phosphorylation sites of CXCR2 that are involved with its desensitization were mutated to alanine residues (4A mutant), the receptor mutant bound weakly to β‐arrestin1 (41% reduction), but exhibited normal binding to AP2 in comparison with WT‐CXCR2 (Figure B). The CXCR2 receptor with both IL/AA (mutant deficient in AP2 binding) and 4A (mutant with reduced binding to β‐arrestin) mutations, designated ‘4A/IL’ mutant, displayed reduced binding to AP2 (64% reduction) as expected and even further reduced binding of β‐arrestin1 (90% reduction), in comparison to the 4A mutant (Figure B) even though β‐arrestin is known to bind with low affinity to GPCRs through the intracellular loops of the receptor . The deficiency of binding of the AP‐2 complex to IL/AA‐CXCR2 mutant has been shown previously .…”
Section: Resultsmentioning
confidence: 81%